Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment-Reference-Cited by-同舟云学术

Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment

Published:2016-06 Issue: Volume:96 Page:7-14
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Epstein Shochet Gali,Israeli-Shani Lilach,Koslow Matthew,Shitrit David

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells;Attar-Schneider;Lab. Invest.,2012

2. Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation;Attar-Schneider;Tumour Biol.,2015

3. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results;Breathnach;J. Clin. Oncol.,2001

4. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression;Buchheit;Nat. Rev. Cancer,2014

5. Lung cancer—time to move on from chemotherapy;Carney;N. Engl. J. Med.,2002

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment;Microvascular Research;2024-07

2. Aberrant TIMP‐1 production in tumor‐associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma;Cancer Science;2024-03-12

3. A 3D culture system for evaluating the combined effects of cisplatin and anti-fibrotic drugs on the growth and invasion of lung cancer cells co-cultured with fibroblasts;APL Bioengineering;2023-03-01

4. Exploring anticancer potential of nintedanib conjugated magnetic nanoparticles: In-vitro and in-silico studies;Journal of Drug Delivery Science and Technology;2023-03

5. Anoikis-Associated Lung Cancer Metastasis: Mechanisms and Therapies;Cancers;2022-09-30